Corrigendum to 'Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial': [Journal of Thrombosis and Haemostasis Volume 22, Issue 6, June 2024, Pages 1704-1714]

Affiliations

• ¹ Vascular Medicine Division, Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota, USA.
• ² Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
• ³ Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
• ⁴ Cardiovascular Division, North Shore University Health System, Evanston, Illinois, USA.
• ⁵ Hematology and Medical Oncology, Siteman Cancer Center, Washington University, St. Louis, Missouri, USA.
• ⁶ Hematology and Medical Oncology, Illinois Cancer Care, Peoria, Illinois, USA.
• ⁷ Hematology Division, University of Washington, Seattle, Washington, USA.
• ⁸ Dean Hematology and Medical Oncology Group, Madison, Wisconsin, USA.
• ⁹ Hematology and Medical Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
• ¹⁰ Hematology and Medical Oncology, Cancer Care & Research Center, Marshfield Clinic, Marshfield, Wisconsin, USA.
• ¹¹ Hematology and Medical Oncology, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.
• ¹² Cardiovascular Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
• ¹³ Hematology Division, Mayo Clinic, Rochester, Minnesota, USA.
• ¹⁴ Montefiore Medical Center, Bronx, New York, USA.
• ¹⁵ University of North Carolina, Chapel Hill, North Carolina, USA.